7 news items
'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
ENVB
16 May 24
Joseph Tucker, Ph.D., director and CEO of Enveric. "EB-003 was designed specifically to address this major safety profile deficiency
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
ENVB
15 May 24
to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
ENVB
14 May 24
2A clinical trial in patients with Major Depressive Disorder, both trials with positive top line data reported. Currently underway are two Phase 2B
Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
ENVB
8 May 24
a major value driver for both Enveric and the licensee.
See also
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
ENVB
8 May 24
trials which would demonstrate a major value driver for both Enveric and the Licensee.
"We are excited
ko887lt
ATAI
CMND
CMPS
20 Mar 24
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive
nfi26fk8ifbe62y8w4vlhzvzuyhi1690qnl
ATAI
BETRF
CMND
16 Mar 24
facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
- Prev
- 1
- Next